Neurons expressing somatostatin receptor 3 (SSTR3) are a subset of somatostatin-expressing neurons found throughout the central nervous system. SSTR3 is one of five somatostatin receptor subtypes (SSTR1-5) that belong to the G protein-coupled receptor (GPCR) superfamily. These receptors mediate the effects of somatostatin, a neuropeptide with widespread inhibitory effects on neuronal excitability and neurosecretion.
SSTR3-expressing neurons are found in:
- Hippocampus — particularly in the dentate gyrus and CA1 region, where they modulate hippocampal circuitry and memory function
- Cerebral cortex — throughout all cortical layers, with higher density in layer 2/3
- Retina — in various retinal neuron populations
- Hypothalamus — involved in neuroendocrine regulation
- Brainstem — in regions controlling autonomic functions
SSTR3 neurons participate in somatostatin-mediated signaling, which:
- Inhibits neurotransmitter release via presynaptic mechanisms
- Reduces neuronal firing rates
- Modulates synaptic plasticity
SSTR3 activation has been shown to provide neuroprotective effects through:
- Inhibition of excitotoxicity
- Reduction of oxidative stress
- Anti-apoptotic signaling pathways
These neurons play roles in:
- Memory consolidation and retrieval
- Spatial navigation
- Attention processes
In the retina, SSTR3 modulates:
- Photoreceptor function
- Retinal ganglion cell activity
- Visual signal processing
SSTR3 expression is altered in Alzheimer's disease:
- Reduced SSTR3 binding has been observed in AD hippocampus
- Somatostatin deficiency is a well-documented feature of AD
- SSTR3 dysfunction may contribute to memory impairment
- Therapeutic potential exists for SSTR3 agonists in AD treatment
- SSTR3 may modulate dopaminergic neuron survival
- Altered somatostatin signaling observed in PD models
- Potential neuroprotective role in substantia nigra
- Altered in depression and mood disorders (comorbid with neurodegeneration)
- Potential role in Huntington's disease
- Implicated in retinal degenerative diseases
SSTR3 couples to Gi/o proteins, leading to:
- Adenylyl cyclase inhibition
- Reduced cAMP production
- Activation of potassium channels
- Hyperpolarization of neurons
- Reduced calcium influx through voltage-gated calcium channels
SSTR3 is being explored as a therapeutic target for:
- Neurodegenerative disease modification
- Cognitive enhancement
- Retinal protection
- Treatment of neurological disorders associated with somatostatin dysfunction
- Somatostatin receptor 3 function in the brain (2019)
- Somatostatin and Alzheimer's disease: Current knowledge (2020)
- SSTR3 neuroprotection in retinal degeneration (2018)
- Somatostatin signaling in hippocampal neurons (2017)
- Neuroprotective effects of SSTR activation (2021)